Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Pfizer chief executive Ian Read is to go head-to-head with AstraZeneca's Pascal Soriot in two parliamentary hearings to argue for the future of the UK-based company. The two CEOs have been called ...

Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an “excess of updated vaccines.” Earlier, Pfizer raised its 2024 guidance to $8.5 billion from $8 ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

The company is already working with multiple large hospitals in the U.S. and Israel, as well as drug companies, including AstraZeneca and Pfizer. Promise Bio is now emerging from stealth with a ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.